Insights

Technology innovations are now able to start realising health concepts that have been talked about for years. As Stephanie Mou explains, insurmountable market advantage awaits the organisation that can establish a compelling delivery platform over the next five years… 

What does the future of next generation implantable drug delivery devices look like? Harry Moorman believes a CC concept breakthrough in smart, miniaturised active implant innovation offers significant opportunity for a market that is ripe for development and commercial growth…

One of the major questions to address when designing a new implantable medical device is how best to power it. Drawing on his extensive knowledge of the field, medical device development expert Neil Rosewell has identified the top six issues around smart implant power that developers need to bear in mind right now…

What can quantum computing and quantum technology do for the pharma and life sciences industry? After reviewing the latest signs of quantum innovation in practice across Europe, Elizabeth Thomas has conferred with Cambridge Consultants’ quantum experts and now shares her insights into how organisations can start implementing an action plan… 

The world of DNA testing is changing fast and the race is on to provide cheap, quick genetic diagnoses for patients. So what are the opportunities for companies working in this dynamic field?

Asia’s medical technology market is predicted to account for a third of global medical technology sales by 2025. As such, it's a hotbed for start-ups, so here are our six innovative start-ups to watch that are part of this year’s MedTech Innovator cohort. 

The design and technology teams working in medical technology innovation at Cambridge Consultants are passionate about improving women’s healthcare. We were delighted to welcome to CC Aashi Srivastava, the winner of Cambridge Consultants ‘Excellence in Breakthrough Design’ at the New Designers award ceremony to hear more about her perineal tear recovery kit to aid new Mums. 

Global pharma is hitting a major fork in the road, and one way leads to failure. For me, it’s vital that the industry comes together to grasp the once-in-a-generation opportunity that emergent technology is offering.

Founders of early-stage start-ups are characteristically passionate, driven and optimistic. Understandably so. Very often they are nurturing a breakthrough idea with the capacity to disrupt business and change the world for the better. So, as they embark on the mission to sell their vision, they should accentuate the positive and keep negative thoughts of risk to the back of their mind, right? Wrong. 

Yan Lin Lye and a team from CC are embarking on a sequence of mentoring sessions as part of our commitment to MedTech Innovator Asia Pacific. For the second consecutive year, we're collaborating with the organisation to provide hands-on professional support to selected start-up participants.

The emergence of cell-based therapy's is one of the most important human stories of our time. Read our synthetic vision of affordable and accessible cell therapy for all...

The pandemic has accelerated our path towards an inevitable conclusion – a digitally connected healthcare future that empowers both patients and carers alike. The opportunities are out there, so what’s the next step for pharma companies and device developers with ambitions in the space?